REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
10/11/2025
Voltar para busca
Dado oficial do USPTO
F-PDO
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
49
Atualização mais recente
11/11/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 42
Data de depósito
17/07/2018
Data de registro
10/11/2020
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
10/11/2020
Última transação
11/11/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
03
Localização do titular
Fukushima, JP
Examinador
CLARKE, NANCY
Unidade examinadora
L20
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
P. U. (pessoa física)
Representantes
John E. Lyhus Fitch, Even, Tabin & Flannery LLP
Classificação técnica
Classes Nice
Classe 1Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Proteins and protein arrays for use in scientific and medical research; enzymes for scientific and research purposes; reagents for analysis and detection of proteinsother than for medical or for medical or veterinary diagnostic use; cells for scientificlaboratorymedical research; medium for cell culture or microbial cultureother than for medical or veterinary diagnostic or medical usecell culture media for scientific and research use; reagents for gene researchother than for medical or veterinary use; inspection reagents for scientific and research purposes consisting of DNA chips and protein chipsother than for medical or for medical or veterinary diagnostic use; blood separating agent in the nature of silicates; albumin from animals or vegetables for scientific and medical research; nucleic acid productsDNARNAoligonucleotidesnucleosides and reagents to conduct sequencing for scientific research purposes other than for medical or for medical or veterinary diagnostic purposes; antibodiesother than for medical or veterinary usebiochemicals in the nature of monoclonal or polyclonal antibodies for in vitro scientific or research use; biological tissue culturesother than for medical or veterinary purposes; chemical reagentskits containing chemical reagents for scientific purposes other than for diagnosticmedical or veterinary purposes; chemicalschemical preparations for scientific purposesother than for medical or for medical or veterinary diagnostic use; plant growth regulatorssubstances for regulating plant growth; plant food; higher fatty acids for use in scientific research; test stripsother than for medical purposeschemically-treated non-medical test strips for calibration of laboratory test equipment; photographic materialsphotographic chemicals; vectorsother than for medical or for medical or veterinary diagnostic purposesnucleic acid products in the nature of molecules for modifying genetic materials in scientific research; plasmidother than for medicalmedical diagnostic or veterinary diagnostic purposesnucleic acid products in the nature of molecules for modifying genetic materials in scientific research
Classe 42
Scientific researchtesting and analysis services in the field of life sciencepharmaceuticalsgeneticscancer detection and treatment; pharmaceutical testinginspectionresearch or development services in the fields of proteinsantibodiesmicroorganisms and cells; pharmaceutical testinginspectionresearch or development in the fields of bacteriologycytologyantibody technologychemistryimmunology and gene expression system; pharmaceutical testinginspectionresearch or development on cell and tissue culture; testinginspectionresearch or development of drugs and biologics for the prevention and treatment of diseases in the fields of autoimmunityinflammationoncologyfibrosis and nerve cell degeneration; testingresearchinspection or development of cancer vaccine; pharmaceutical testinginspectionresearch or development of clinical trialsdrugsbiologics for the medical treatment of cancer; testinginspectionresearch or development on genesregarding genetic mutation and expression profileproviding information relating theretoin the field of genetics and genetic engineering; providing information on testinginspection or research on DNA sequenceRNA sequence or amino acid sequence of protein in the field of life science; analysis or screening of DNARNA or protein in the field of life science for scientific research purposes; testinginspection or research of pharmaceuticalschemicalscosmeticsreagents and foodsproviding scientific advice and information on the foregoing; quality evaluation for others in the field of pharmaceuticals and clinical trials; providing quality assurance services in the field of pharmaceuticals and clinical trials; medical and scientific research in the field of medical treatments for cancers and providing consultation and information on the foregoing; testing and research in the field of biotechnology and providing consultation and information on the foregoing; testing and research in the field of geneticsproviding information on the foregoing; research and consultancy in the field of zoology; testinginspection or research of pharmaceuticalscosmetics or foodstuffs; research on building construction or city planning; testing or research on prevention of pollution; testing or research on electricity; testing or research on civil engineering; testinginspection or research on agriculturelivestock or fisheries; testing the functionality of machinesresearch on machines and laboratory apparatus and instruments; design for others of machinery and scientific research equipmentincluding design for others of the structural parts comprising the foregoing machinery and equipment; providing information and advice on computer system design and use of information technology to process information in the medical fieldsaid information and advice provided via computer; computer software designcomputer programmingmaintenance of computer software; providing temporary use of on-linenon-downloadable computer programs for medical image analysis via computers; rental of computers; providing temporary use of on-linenon-downloadable computer programs on data networks for the purpose of gatheringmanaging and reporting on scientific dataresearch and analysis
Publicações
Histórico de despachos e eventos da marca no USPTO.
49 publicações encontradas
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
04/04/2021
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
18/02/2021
XXCR
GENERIC MADRID TRANSACTION CREATED
18/02/2021
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
10/02/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
10/11/2020
GPNX
NOTIFICATION PROCESSED BY IB
25/08/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
25/08/2020
PUBO
PUBLISHED FOR OPPOSITION
25/08/2020
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
05/08/2020
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
05/08/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/08/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
22/07/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
25/06/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
25/06/2020
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
24/06/2020
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
17/04/2020
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
06/04/2020
GNFR
FINAL REFUSAL E-MAILED
06/04/2020
CNFR
FINAL REFUSAL WRITTEN
06/04/2020
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
01/04/2020
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
01/04/2020
XAEC
EXAMINER'S AMENDMENT ENTERED
24/02/2020
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
24/02/2020
GNEA
EXAMINERS AMENDMENT E-MAILED
24/02/2020
CNEA
EXAMINERS AMENDMENT -WRITTEN
24/02/2020
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
06/02/2020
GNFR
FINAL REFUSAL E-MAILED
06/02/2020
CNFR
FINAL REFUSAL WRITTEN
06/02/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/01/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/01/2020
ALIE
ASSIGNED TO LIE
04/01/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
18/12/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
29/06/2019
GNRT
NON-FINAL ACTION E-MAILED
29/06/2019
CNRT
NON-FINAL ACTION WRITTEN
29/06/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/06/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/06/2019
ALIE
ASSIGNED TO LIE
05/06/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
31/05/2019
RFNT
REFUSAL PROCESSED BY IB
21/12/2018
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
04/12/2018
RFRR
REFUSAL PROCESSED BY MPU
04/12/2018
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
16/11/2018
CNRT
NON-FINAL ACTION WRITTEN
15/11/2018
MAFR
APPLICATION FILING RECEIPT MAILED
13/11/2018
DOCK
ASSIGNED TO EXAMINER
07/11/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/11/2018
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
01/11/2018
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace F-PDO ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.